Yesterday, Precigen Inc (NASDAQ: PGEN ) agreed to sell its non-healthcare subsidiary to URUS.
HC Wainwright says they are encouraged by the divestiture of the company's non-core business and believe management deserves much credit, especially against the backdrop of the challenging macro environment.
Related: Why Precigen Shares Are Gaining Today ?
The analyst believes the completed transaction would remove the financial overhang related to the approximate $200 million convertible notes that mature in July 2023.
The company ... Full story available on Benzinga.com